Hypopharyngeal Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hypopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.
The Hypopharyngeal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hypopharyngeal Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 89 molecules, with 87 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hypopharyngeal Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hypopharyngeal Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hypopharyngeal Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAdvenchen Laboratories LLC
Akeso Inc
Angel Pharmaceuticals Inc
Ascendis Pharma AS
Ascenta Therapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
BeiGene Ltd
Bicara Therapeutics Inc
BioAtla Inc
Biomimetix JV LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chugai Pharmaceutical Co Ltd
Compass Therapeutics Inc
Compugen Ltd
CSPC Pharmaceutical Group Ltd
Dragonfly Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Exelixis Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Gilead Sciences Inc
GSK plc
I-Mab
Icahn School of Medicine at Mount Sinai
Incyte Corp
Innolake Biopharm Co Ltd
Innovent Biologics Inc
IO Biotech Inc
Janssen Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Lisata Therapeutics Inc
Mabpharm Ltd
Merck & Co Inc
Merck KGaA
Moderna Inc
Natco Pharma Ltd
NeoImmuneTech Inc
Novartis AG
Nubiyota LLC
Nykode Therapeutics ASA
Pfizer Inc
POINT Biopharma Global Inc
Prelude Therapeutics Inc
Puretech Health Plc
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Sanofi
Scancell Holdings Plc
Seagen Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Miracogen Inc
SinoCelltech Group Ltd
Systimmune Inc
UNC Lineberger Comprehensive Cancer Center
VasGene Therapeutics Inc
Zhuhai Beihai Biotech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hypopharyngeal Cancer reports